Valsts: Austrālija
Valoda: angļu
Klimata pārmaiņas: Department of Health (Therapeutic Goods Administration)
bortezomib, Quantity: 1 mg
Dr Reddys Laboratories Australia Pty Ltd
Injection, powder for
Excipient Ingredients: mannitol
Intravenous
1
(S4) Prescription Only Medicine
BORTEZOMIB-DR.REDDY?S, in combination with melphalan and prednisone is indicated for the treatment of patients with previously untreated multiple myeloma who are not candidates for high dose chemotherapy. BORTEZOMIB-DR.REDDY?S, as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma. BORTEZOMIB-DR.REDDY?S is also indicated for the treatment of multiple myeloma patients who have received at least one prior therapy, and who have progressive disease. BORTEZOMIB-DR.REDDY?S in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma.
Visual Identification: A white to off-white sterile lyophilized powder; Container Type: Vial; Container Material: Glass Type I Coloured; Container Life Time: 9 Months; Container Temperature: Store below 25 degrees Celsius
Licence status A
2020-09-21